[Clinical observation on hypercortisolism treated with amino-glutethimide].
We reported the clinical results in 13 cases of hypercortisolism treated with amino-glutethimide (AG), which was developed by Tiantsin Research Institute of Medical Industry. Of the thirteen cases nine were confirmed by surgery and histology, and the others were diagnosed clinically. Clinical improvements have been achieved in ten of the thirteen cases over a therapeutic course of 8 to 12 wk with a daily dosage of 1.0 to 2.0 g of AG. Plasma and urinary corticosteroids, as well as plasma testosterone levels were significantly decreased after one-month treatment followed, however, by somewhat return and fluctuation. The high levels of blood glucose and serum insulin were declined after therapy consistent with the decrement of corticoids. Serum potassium levels in hypokalemic patients returned to normal after one month of therapy. Radial bone mineral contents in patients with low bone density returned or closed to normal after three-month treatment. The main side effects of AG are anorexia, nausea, drowsy, tierdness, skin rashes, etc, which are mild and transient. Adrenal hypofunction was seen in one case after treatment.
Li
X J
XJ
Liang
J Z
JZ
Tian
H M
HM
Li
Y
Y
Cai
F
F
Yang
D P
DP
Cheng
Y M
YM
Yu
Z L
ZL
D000293:Adolescent; D000308:Adrenocortical Hyperfunction / Q000188:drug therapy*; D000328:Adult; D000616:Aminoglutethimide / Q000009:adverse effects / Q000627:therapeutic use*; D001066:Appetite / Q000187:drug effects; D001842:Bone and Bones / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D008903:Minerals / Q000378:metabolism
D008903:Minerals; D000616:Aminoglutethimide